Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Список исп. литературыСкрыть список 1. Diagnostic and statistical manual of mental disorders. 5th ed. Text revision (DSM-5). Washington, DC. American Psychiatric Press 2013. 2. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002; 16: 162–71. 3. Tyrer P et al. The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med 2004; 34 (8): 1385–94. 4. Munk-Jorgensen et al. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland and Norway. Psychiat Serv 2006; 57 (12): 1738–44. 5. Bandelow B, Zohar J et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiat 2008; 9 (4): 248–312. 6. Hidalgo et al. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21: 864–72. 7. Baldwin et al. Evidence-based pharmacotherapy of generalized anxiety disorder. Essential Evidence-based psychopharmacol. Cambridge University Press 2013; p. 112–4. 8. Bruce et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiat 2005; 162 (6): 1179–87. 9. Allgulander et al. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006; 9: 495–505. 10. Stocchi et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder J Clin Psychiat 2003; 64 (3): 250–8. 11. Feltner et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23 (3): 240–9. 12. Davidson et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Neuropsychopharmacol 2008; 18 (9): 673–81. 13. Chessick et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; 3: CD006115. 14. Rickels et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiat 2003; 160: 749–56. 15. Baldwin et al. Antipsychotic drugs in the treatment of generalized anxiety disorder. Int J Psychiat Clin Pract 2009; 13: s2. 16. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiat 2007; 40 (4): 163–8. 17. Rickels et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol 2012; 27 (3): 142–50. 18. Bandelow B et al. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiat 2007; 8 (3): 175–87. 19. Leonardo E. Anxiety as a developmental disorder. Neuropsychopharmacol 2008; 33 (1): 134–40.